MONTREAL, 20 April 2006 - Concerns about the use of letrozole, an easy-to-use and inexpensive drug for the treatment of infertility, appear to be unfounded, according to a major study coauthored by Dr. Togas Tulandi, Director of Division of Reproductive Endocrinology and Infertility, McGill University Health Centre (MUHC) and Chief of Obstetrics and Gynecology at the Jewish General Hospital, and Professor of Obstetrics and Gynecology at McGill University. Their findings, which are currently available in an early online edition of Fertility and Sterility, showed that babies whose mothers were treated with letrozole had the same rate of birth defects as those whose mothers were treated with clomiphene citrate the low-risk, first-line treatment for infertility for more than 40 years.

"We found no statistically significant difference in the overall rates of major and minor malformations or chromosomal abnormalities between newborns in the two groups," says Dr. Tulandi. "Our findings indicate concerns about a link between letrozole and birth defects are unfounded. This is significant because it confirms that letrozole can indeed be used in the treatment of infertility without increasing risk to the fetus."

The study contradicts an earlier, much smaller study linking letrozole to increased rates of inherited malformations. This study led to widespread concern about the use of letrozole, a drug which has been widely used in the treatment of infertility in recent years.

"There were several methodological problems with the earlier study," says Dr. Tulandi. "For one thing, it compared the incidence of birth defects in children conceived spontaneously with that in children conceived through fertility treatments using letrozole. This is an apples-and-oranges comparison, because there are always fewer birth defects in children conceived spontaneously." The earlier study also compared different age groups between the control and treatment.

The ne
'"/>

Contact: Ian Popple
Ian.popple@muhc.mcgill.ca
514-843-1560
McGill University
20-Apr-2006

Page: 1 2
Related medicine news :

1. UIC researchers to develop new drugs to fight bioterrorism
2. Statin drugs may delay progressive artery damage in children
3. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
4. Experts call for urgent research into anti-epileptic drugs given to children
5. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
6. Antipsychotic drugs increase risk of death in older people with dementia
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
9. Panel offers guidelines on skin reactions to new class of cancer drugs
10. Blood-thinning drugs need closer monitoring
11. Comparison of patients access to new and better cancer drugs reveals inequalities between countries